SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major trending topic as its Q4 earnings, which beat expectations, were met with a significant stock dip, fueling intense debate among investors. The community is sharply divided, with many viewing the sharp decline as a prime 'buy the dip' opportunity for a long-term hold, citing strong fundamentals. Conversely, bears are expressing concerns over cautious guidance, the implications of its Warner Bros. Discovery acquisition, increased content spending, and the pausing of share buybacks.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is a hot topic as the community anticipates significant announcements, fueled by recent industry awards and confirmation of continued work with Celestial AI, now part of Marvell. Discussion centers on POET's patented optical interposer technology, seen as a crucial solution for the escalating demand for high-speed, power-efficient optical interconnects in AI data centers. Many believe the company is poised for major customer orders, positioning it as a key player in the ongoing optical supercycle.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as gold surges, fueled by escalating geopolitical tensions, including discussions around Trump's tariff threats against European nations and the Greenland issue. The community is actively debating if this signifies a sustained shift towards real assets due to eroding trust in fiat currencies, or if it's a momentum-driven rally susceptible to de-escalation.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is experiencing a highly polarized trend following a rapid price surge, sparking intense community debate. While many celebrate substantial gains and anticipate further rallies, a vocal segment warns of a potential "rug pull" or pump-and-dump, cautioning investors due to its meme coin characteristics. Amidst this volatility, new participants are actively seeking information on how to acquire the token.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is actively discussed amid its upcoming separation into two independent companies and the appointment of a new CEO, with many anticipating this will unlock significant value. Community sentiment is polarized between those who see current price levels as a rare buying opportunity and those concerned about it being a "value trap," often fueled by claims of market manipulation and recent analyst downgrades.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust (SPY) is actively trending amid heightened geopolitical rhetoric, particularly surrounding discussions of a potential U.S. acquisition of Greenland and associated tariff implications. The community is sharply divided, with many anticipating a significant rebound from a recent market dip, while others express concerns about escalating global tensions and upcoming public statements from a prominent political figure. Broader market sentiment is currently influenced by a tug-of-war between 'buy the dip' enthusiasm and fears of further instability affecting international asset holdings.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following significant insider share purchases, including CEO Ryan Cohen's acquisition of 500,000 shares. This has ignited strong bullish sentiment within the community, with many interpreting the buys as a powerful signal of conviction and a potential catalyst for a renewed short squeeze. Investors are actively discussing the company's strong balance sheet and lack of debt, anticipating a major move for the meme stock.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is experiencing significant volatility, with recent analyst downgrades sparking accusations of market manipulation and creating confusion among investors despite the company's strong AI server demand and increased revenue guidance. While many in the community view the recent price dip as a prime buying opportunity given its low valuation and record AI server backlog, others remain cautious amid concerns over memory price inflation and competitive pressures in the AI infrastructure market.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is trending due to renewed tariff threats from a US political figure concerning an international territory, fueling global trade war fears. This has sparked widespread community discussion, with many anticipating significant market volatility and potential capital flight, while others remain optimistic about a swift market rebound amid broader geopolitical tensions.

Virtu Financial, Inc. engages in the provision of trading solutions and liquidity services. It operates through the following segments: Market Making, Execution Services, and Corporate. The Market Making segment involves the cash, futures, and options markets across global equities, fixed income, currencies, cryptocurrencies, and commodities. The Execution Services segment includes agency-based, execution-only trading, workflow technology, and trading analytics. The Corporate segment consists of investments in financial services-oriented opportunities and maintains corporate overhead expenses and all other income and expenses that are not attributable to the other segments. The company was founded by Vincent J. Viola and Douglas A. Cifu in 2008 and is headquartered in New York, NY.

Virtu Financial Inc - Ordinary Shares - Class A

Virtu Financial is trending due to robust earnings reports that have consistently exceeded expectations, fueled by sustained market volatility and high trading volumes, including growing crypto market participation. While many are optimistic about its market-making operations, a vocal community segment remains critical, often linking the company to allegations of market manipulation and ongoing lawsuits. This dual narrative highlights intense, contrasting discussions surrounding its operational success and perceived controversies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood, Founder & CEO, Ark Invest, speaks during the second day of the FII PRIORITY Summit

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

Equity

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.


A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena. (Photo by Sarah Reingewirtz/MediaNews Group/Los Angeles Daily News via Getty Images)

Nano-Cap Regentis Biomaterials Stock Is Up Nearly 15% This Year: Why Retail Traders Are Swarming It

Heading to close this week as its best week since IPO, RGNT has become a retail favorite with surging followers on Stocktwits.

MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab

The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials.

Currency and Exchange Stock Chart for Finance and Economy Display. (Image Courtesy: Getty Images)

TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally

Strong 2026 guidance and accelerating uptake of its MS drug send TGTX to its best session in months, with Wall Street and retail piling in.

<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul><p>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;</p><p>On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.</p><h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><p><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure><p>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.</p><p><stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl></p><p>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;</p><p><stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl></p><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2><p>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;</p><p>Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.</p><p>BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.</p><h2 class="st-heading-2">Upcoming Clinical Milestones</h2><p>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;</p><p>Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;</p><p>TGTX stock has declined by over 6% in the last 12 months.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

December Jobs Data Put Focus on These Sector ETFs & Stocks

December jobs data highlight sector shifts as healthcare and restaurants add jobs, while retail lags. ETFs XLV, EATZ in focus.

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul><p>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;</p><p>The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</p><h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2><p>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;</p><p>Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;</p><blockquote><p>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”</p><p>-Scott Hutton, CEO, Biodesix</p></blockquote><p>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2><p>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;</p><p>“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;</p><p>Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;</p><p>BDSX stock declined by over 77% in the last 12 months.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond

After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.

<ul class="summary-bullets"><li>Booth said timing drove sharply different investor outcomes in Ventyx.</li><li>Clear Street said Lilly was a logical buyer and cut Ventyx to ‘Hold’.</li><li>LifeSci Capital said the stock reset to ‘Market Perform’ after the deal.</li></ul><p>Ventyx’s path through public markets culminated in a $1.2 billion buyout by&nbsp;Eli Lilly, highlighting how timing drove investor outcomes, ranging from deep drawdowns to more than 2,000% upside.</p><p>That contrast was captured by Atlas Venture partner Bruce Booth,&nbsp;an early-stage biotech venture capitalist who&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/LifeSciVC/status/2009081510192914652">said on X</a>&nbsp;that the stock’s history has become a case study in how biotech returns can be dictated less by belief and more by when investors&nbsp;choose to step in.</p><h2 class="st-heading-2"><strong>Bottom Buyers Reaped The Gains</strong></h2><p>Booth said investors who bought Ventyx shares near the lows in early 2025 would have seen gains of more than 2,000% by the time the company agreed to be acquired. He added that investors who bought at the IPO ultimately got most of their money back, which he described as a win, given that the stock had been more than 90% underwater a year earlier.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260108_095534478_png_dfe989a876.webp" alt="koyfin_20260108_095534478.png" width="2400" height="1240"></figure><h2 class="st-heading-2"><strong>From Early Optimism To Strategic Reset</strong></h2><p>When Ventyx went public, its main drug program targeted TYK2, a protein involved in immune system signaling that is linked to autoimmune and inflammatory diseases. Over time, the company pivoted toward the NLRP3 inflammasome, reshaping its pipeline to focus on inflammatory, cardiometabolic, and neurodegenerative diseases.</p><p>That strategic reset proved critical. Lilly said the acquisition&nbsp;strengthened its position in cardiometabolic health, immunology, and neuroscience, while filling a gap in NLRP3 assets that could pair with its existing therapies.</p><p>Clear Street, which downgraded Ventyx to ‘Hold’ from ‘Buy’ following the deal, described Lilly as a “logical” buyer, noting that Ventyx’s inflammasome-focused portfolio complements Lilly’s franchises and addresses an area where Lilly previously lacked assets.&nbsp;</p><h2 class="st-heading-2"><strong>Clinical Data Sustained Interest Through&nbsp;</strong></h2><p>Despite extreme share price swings, Ventyx continued to generate clinical updates that kept its science in focus. In June, the company reported positive Phase 2a results for VTX3232 in early Parkinson’s disease. The study showed that the drug was safe and well-tolerated, reached the brain as intended, and reduced key inflammation-related biomarkers, indicating that it engaged its intended target.</p><p>VTX3232 targets NLRP3, a protein involved in driving inflammation in neurodegenerative diseases. In January 2025, H.C. Wainwright described Ventyx’s Phase 2 pipeline as high risk/high reward, citing both the potential of this inflammation-focused approach and the long history of difficulty in developing effective treatments for neurodegenerative disorders.</p><h2 class="st-heading-2"><strong>Wall Street Reframes After The Buyout</strong></h2><p>With the acquisition agreement in place, analysts moved to align ratings with the deal terms. LifeSci Capital downgraded Ventyx to ‘Market Perform’ from ‘Outperform’, setting a $14 price target after the company agreed to be acquired. Clear Street made a similar move, cutting the stock to ‘Hold’ from ‘Buy’ while raising its target from $11 to $14.</p><p>By contrast, UBS initiated coverage with a ‘Buy’ rating on Tuesday, citing improving biotech fundamentals, a recovering risk appetite, and Ventyx’s pipeline as among several small- and mid-cap biotech stories positioned for stronger performance in 2026.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Ventyx was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/vtyx_ss_png_0e1eef59df.webp" alt="vtyx ss.png" width="969" height="141"><figcaption>VTYX sentiment and message volume as of January 7| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/VTYX">Ventyx’s stock</a> has surged 467% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Ventyx’s stock (VTYX) has surged 467% over the past 12 months. (Representative Image: Getty Images)

Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains

Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.

Bank of America shares S&P 500 warning for 2026

The stock market's under duress, but Wall Street's biggest banks feel it's still pretty expensive. Bank of America warns that theS&P 500 is priced for perfection as we progress deeper into 2026...

SSgA Active Trust - State Street Health Care Select Sector SPDR ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLV News

XLVHealth Care Select Sector SPDR Fund